zosuquidar + daunorubicin + cytarabine

**zosuquidar + daunorubicin + cytarabine** is an investigational combination therapy evaluated for the treatment of acute myeloid leukemia (AML), particularly in elderly patients. Zosuquidar is a potent and highly specific inhibitor of P-glycoprotein (P-gp, ATP Binding Cassette Transporter, Subfamily B, Member 1), a membrane efflux pump implicated in multidrug resistance in cancer cells[1][2][3][5]. Daunorubicin is an anthracycline antineoplastic agent and cytarabine is a cytosine nucleoside analog; both are core components of AML chemotherapy regimens. Zosuquidar is co-administered to block P-gp and potentially sensitize leukemic cells to the cytotoxic effects of daunorubicin and cytarabine. In clinical studies, zosuquidar is typically administered via continuous intravenous infusion for 72 hours, aiming to maintain effective P-gp inhibition during chemotherapy administration[1][3][5].

Other names

zosuquidar trihydrochloride + daunorubicin + cytarabine